Product Spotlight: Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide)
- Thu, 10/28/10 - 9:01am
- 0 Comments
- 1201 reads
Tribenzor (olmesartan medoxomil [OM], amlodipine [AML], hydrochlorothiazide [HCTZ]) is a 3-in-1 combination product for the treatment of hypertension in patients who are not adequately controlled on any 2 of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics at their maximally tolerated, labeled, or usual dose.
Xifaxan (rifaximin)
- Mon, 6/28/10 - 2:05pm
- 0 Comments
- 642 reads
Xifaxan (rifaximin) is a rifamycin antibiotic that is gut selective with negligible systemic absorption and broad-spectrum activity in vitro against both gram-positive and gram-negative pathogens. The drug is minimally absorbed and concentrates in the gastrointestinal tract.
Rifaximin was recently approved for reduction in risk of overt hepatic encephalopathy recurrence in patients ≥18 years of age. The product is also indicated for treatment of patients ≥12 years of age with travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
Hepatic encephalopathy
Actemra (tocilizumab)
- Mon, 5/24/10 - 9:44am
- 0 Comments
- 1166 reads
Actemra (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor used to treat adults with moderate-to-severe rheumatoid arthritis (RA) who have not adequately responded to or cannot tolerate other approved drug classes for treating rheumatoid arthritis. The drug is a humanized monoclonal antibody that works by blocking the action of IL-6, an immune system protein that is overabundant in people with RA.
Product Spotlight - Ampyra
- Thu, 3/18/10 - 2:56pm
- 0 Comments
- 1581 reads
Ampyra (dalfampridine) is a potassium channel blocker taken orally as a treatment to improve walking in patients with multiple sclerosis (MS). Ampyra, previously referred to as Fampridine-SR, is provided in an extended-release tablet formulation of dalfampridine, which was previously called fampridine. The name was changed to dalfampridine to avoid confusion with other FDA-approved products.
The efficacy of dalfampridine for this indication was demonstrated by an increase in walking speed. The product was granted orphan drug status, providing
Product Spotlight - Saphris
- Thu, 1/28/10 - 2:39pm
- 0 Comments
- 2106 reads
Saphris
(asenapine)
Saphris (asenapine) is an atypical antipsychotic indicated for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Asenapine is administered via 5-mg or 10-mg sublingual tablets that are placed under the tongue and allowed to dissolve completely. For schizophrenia, the recommended starting dose of asenapine is 5 mg twice daily. For bipolar disorder the recommended starting dose is 10 mg twice daily, and the dose can be decreased to 5 mg twice daily if pati
Get your Trends Smart Phone Mobile App Now!
